- 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- 89bio to Participate in the BofA Securities 2024 Health Care Conference
- 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
- 89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
- 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
- 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
As of last trade, 89Bio Inc (ETNB:NMQ) traded at 8.33, 26.69% above the 52 week low of 6.58 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.01 |
---|---|
High | 9.01 |
Low | 8.31 |
Bid | 8.31 |
Offer | 8.34 |
Previous close | 8.93 |
Average volume | 671.56k |
---|---|
Shares outstanding | 98.38m |
Free float | 97.69m |
P/E (TTM) | -- |
Market cap | 878.57m USD |
EPS (TTM) | -2.01 USD |
Data delayed at least 15 minutes, as of May 23 2024 16:07 BST.
More ▼